아시아태평양의 생물제제 Drug Discovery 시장 : 제조 유형, 유형, 국가별 분석 및 예측(2025-2035년)
Asia-Pacific Biologics Drug Discovery Market: Focus on Manufacturing Type, Type, and Country - Analysis and Forecast, 2025-2035
상품코드:1892738
리서치사:BIS Research
발행일:2025년 12월
페이지 정보:영문
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
아시아태평양의 생물제제 Drug Discovery 시장 규모는 2024년 48억 7,000만 달러에서 2025년부터 2035년까지의 예측 기간 동안 CAGR 11.90%를 나타내 2035년에는 167억 1,000만 달러에 달할 것으로 예상됩니다.
만성 질환과 희귀질환 증가, 정밀의료로의 가속적인 전환 추세에 대응하는 가운데, 아시아태평양의 생물제제 Drug Discovery 시장은 현저한 성장을 이루고 있습니다. 단일클론항체, 재조합 단백질, 차세대 모달리티 등의 바이오로직은 전통적인 저분자 의약품보다 뛰어난 치료 효과와 높은 특이성을 제공하기 때문에 아시아태평양 전체에서 점점 보급되고 있습니다. 중국, 일본, 한국, 인도, 호주 등의 국가에서의 산학 연계의 확대, 정부 주도의 연구 개발 프로젝트, 규제 프레임워크의 변화가 이 지역의 진전에 기여하고 있습니다.
주요 시장 통계
예측 기간
2025-2035년
평가(2025년)
54억 3,000만 달러
예측(2035년)
167억 1,000만 달러
CAGR
11.9%
아시아태평양의 Drug Discovery 환경은 기술 진보에 따라 빠르게 변화하고 있습니다. AI를 활용한 표적 발견, 고처리량 스크리닝, 멀티오믹스 플랫폼, 첨단 항체 설계 툴의 통합으로 이 지역의 혁신 능력이 강화되어 초기 단계의 효율성이 향상되고 있습니다. 그러나 연구 인프라의 불균일성, 규제 성숙도의 변동, 높은 개발 비용, 일부 국가의 바이오 의약품 제조 능력의 제약 등의 장벽은 여전히 진보 속도에 영향을 미치고 있습니다. 그러나 투자 증가, 지역의 CRO 및 CDMO로의 아웃소싱의 확대, 개별화 베이스로 메커니즘에 근거한 치료법에 대한 수요 가속에 의해 이 지역은 바이오 의약품 개발 및 장래의 치료 혁신의 급속하게 발전하는 거점이 되고 있습니다.
시장 개요
희소질환과 만성질환 증가, 개인화 치료에 대한 수요 증가, 지역의 의료 인프라 정비가 진행되고 있는 것이, 아시아태평양의 생물제제 Drug Discovery 시장의 현저한 성장에 기여하고 있습니다. 정부 자금에 의한 연구 프로젝트, 산학 연계, 전문적인 CRO와 CDMO 네트워크의 확대에 의해 중국, 일본, 한국, 인도, 호주 등의 국가들은 바이오로직스의 연구 개발에 있어서 중요한 거점이 되고 있습니다. 단일클론항체, 재조합 단백질, 다중특이적 항체 및 유전자 치료와 같은 차세대 모달리티를 포함하는 생물학적 기술은 기존의 저분자 의약품보다 특이성이 높고 효과적이고 안전하기 때문에 점점 보급되고 있습니다.
기술 혁신으로 인해 이 지역의 Drug Discovery 파이프라인은 가속화되고 있습니다. 고급 항체 공학, 멀티오믹스 통합, 고처리량 스크리닝, AI를 활용한 표적 발견 기술이 초기 단계의 연구 효율성과 성공률을 향상시키고 있습니다. 게다가 디지털 기술과 리얼 월드 데이터의 활용으로 바이오마커 주도의 Drug Discovery 개발과 정밀의료 전략이 진화하고 있습니다.
이러한 진전에도 불구하고 급등하는 연구 비용, 복잡한 제조 사양, 지역별 규제 성숙도 및 자격 인력의 차이 등 여전히 많은 장벽이 존재하고 있습니다. 그러나 아웃소싱 모델의 확대, 관민 부문 투자 증가, 맞춤형 의료에 대한 관심이 높아짐에 따라 아시아태평양은 바이오로직스 의약품의 급속히 발전하는 거점으로 자리매김해 향후 10년간 세계의 치료 혁신에 크게 공헌할 가능성을 지니고 있습니다.
시장 분류 :
세분화 1 : 제조 유형별
내부 제조
외주 제조
세분화 2 : 유형별
단일클론항체
재조합 단백질
기타 생물학적 제제
세분화 3 : 지역별
아시아태평양
중국
일본
인도
한국
호주
기타
본 보고서에서는 아시아태평양의 생물제제 Drug Discovery 시장을 조사했으며, 주요 동향, 시장영향인자 분석, 법규제 환경, 시장 규모 추이와 예측, 각종 구분·지역/주요 국가별 상세 분석, 경쟁 구도, 주요기업의 프로파일 등을 정리했습니다.
목차
주요 요약
범위 및 정의
제1장 생물제제 Drug Discovery 시장 : 업계 전망
시장 개요
주요 시장 동향
이중특이적 항체 및 다중특이성 항체 개발의 성장
파트너십 및 협업 증가
아웃소싱 서비스 수요 증가
규제 상황
아시아태평양
공급망 분석
공급망과 공급망 내의 위험
특허 분석
특허출원 동향(국가별)
특허출원 동향(연별)
시장 역학
시장 성장 촉진요인
시장 과제
시장 기회
제2장 생물제제 Drug Discovery 시장 : 지역별
아시아태평양
지역 개요
시장 성장의 원동력
시장 과제
시장 규모와 예측
제3장 경쟁 벤치마킹·기업 프로파일
기업 프로파일
Astellas Pharma Inc.
GenScript Biotech Corporation
WuXi Biologics(Cayman) Inc.
제4장 조사 방법
KTH
영문 목차
영문목차
This report can be delivered in 2 working days.
Introduction to Asia-Pacific Biologics Drug Discovery Market
The Asia-Pacific biologics drug discovery market is projected to reach $16.71 billion by 2035 from $4.87 billion in 2024, growing at a CAGR of 11.90% during the forecast period 2025-2035. As the region deals with an increasing number of chronic and rare diseases as well as an accelerating trend toward precision-focused medicines, the APAC biologics drug development market is gaining significant traction. Because they provide better therapeutic outcomes and greater specificity than conventional small drugs, biologics-such as monoclonal antibodies, recombinant proteins, and next-generation modalities-are becoming more and more popular throughout APAC. Growing academic-industry collaborations, government-led R&D projects, and changing regulatory frameworks in nations like China, Japan, South Korea, India, and Australia all contribute to the region's advancement.
KEY MARKET STATISTICS
Forecast Period
2025 - 2035
2025 Evaluation
$5.43 Billion
2035 Forecast
$16.71 Billion
CAGR
11.9%
APAC's discovery landscape is rapidly changing due to technological improvements. The region's ability for innovation is being strengthened and early-stage efficiency is being improved through the integration of AI-driven target identification, high-throughput screening, multi-omics platforms, and sophisticated antibody-engineering tools. Despite this expansion, obstacles like uneven research infrastructure, inconsistent regulatory maturity, high development costs, and restricted biologics manufacturing capacity in some countries continue to influence the rate of advancement. Nevertheless, APAC is becoming a rapidly developing center for biologics drug development and future therapeutic innovation due to growing investments, increasing outsourcing to regional CROs and CDMOs, and accelerated demand for individualized and mechanism-based treatments.
Market Introduction
The growing prevalence of uncommon and chronic diseases, the growing need for tailored treatments, and the development of the region's healthcare infrastructure are all contributing factors to the APAC biologics drug discovery market's notable expansion. With the help of government-funded research projects, industry-academia partnerships, and an expanding network of specialized CROs and CDMOs, nations like China, Japan, South Korea, India, and Australia are becoming important centers for biologics R&D. Because they are more specific, effective, and safe than traditional small drugs, biologics-which include monoclonal antibodies, recombinant proteins, and next-generation modalities like multispecific antibodies and gene therapies-are becoming more and more popular.
The region's discovery pipelines are being accelerated by technological advancements. Advanced antibody engineering, multi-omics integration, high-throughput screening, and AI-driven target discovery are increasing the effectiveness and success rates of early-stage research. Furthermore, the use of digital technologies and real-world data is improving biomarker-driven drug development and precision medicine strategies.
Notwithstanding these developments, there are still many obstacles to overcome, including expensive research costs, intricate manufacturing specifications, and differences in regulatory maturity and qualified personnel within APAC markets. However, growing outsourcing models, rising public and private sector investment, and an increasing emphasis on personalized medicine are positioning APAC as a rapidly developing hub for biologics drug discovery, with the potential to make a substantial contribution to global therapeutic innovation over the next ten years.
Market Segmentation:
Segmentation 1: By Manufacturing Type
In-House Manufacturing
Outsourced Manufacturing
Segmentation 2: By Type
Monoclonal Antibodies
Recombinant Proteins
Other Biologics
Segmentation 3: By Region
Asia-Pacific
China
Japan
India
South Korea
Australia
Rest-of-Asia-Pacific
APAC Biologics Drug Discovery Market Trends, Drivers and Challenges
Market Trends
Strong adoption of monoclonal antibodies, recombinant proteins, and next-generation biologics such as gene and cell therapies.
Increasing use of AI, machine learning, and computational tools for target identification and lead optimization.
Expansion of public-private partnerships and collaborations between pharma, biotech, and academic institutions.
Growing outsourcing to regional CROs and CDMOs for specialized biologics R&D and manufacturing.
Rising focus on precision medicine and biomarker-driven approaches across therapeutic areas like oncology, immunology, and neurology.
Market Growth Drivers
Rising prevalence of chronic, autoimmune, and rare diseases across APAC, fueling demand for innovative biologics.
Government-backed R&D funding and supportive regulatory frameworks enhancing research capabilities.
Technological advancements, including high-throughput screening, multi-omics analysis, and antibody engineering.
Increasing investments from pharma, biotech, and venture capital supporting early-stage discovery.
Adoption of digital tools and real-world evidence to optimize drug development and clinical success rates.
Market Challenges
High development and manufacturing costs for biologics, particularly for advanced modalities.
Regulatory variability across APAC countries creating delays and complexity in approvals.
Limited skilled talent in biologics discovery, CMC, and regulatory sciences in certain markets.
Infrastructure disparities, including availability of specialized labs and biologics manufacturing facilities.
Supply-chain vulnerabilities for APIs and reliance on regional CDMOs, leading to potential delays and cost pressures.
How can this report add value to an organization?
Product/Innovation Strategy: The APAC biologics drug discovery market has been extensively segmented based on various categories, such as manufacturing type, type, and region. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.
Growth/Marketing Strategy: Partnerships, alliances, and business expansions have accounted for the majority of key developments.
Competitive Strategy: The APAC biologics drug discovery market has numerous established players with product portfolios. Key players in the APAC biologics drug discovery market, analyzed and profiled in the study, include established players offering platforms, products, and services for biologics drug discovery.
Key Market Players and Competition Synopsis
The companies profiled have been selected based on inputs gathered from an analysis of company coverage, product portfolio, and market penetration.
Some prominent names established in this market are:
Astellas Pharma Inc.
GenScript Biotech Corporation
WuXi Biologics (Cayman) Inc.
Table of Contents
Executive Summary
Scope and Definition
1 Biologics Drug Discovery Market: Industry Outlook
1.1 Market Overview
1.2 Key Market Trends
1.2.1 Growth of Bispecific and Multispecific Antibody Development
1.2.2 Rising Partnerships and Collaborations
1.2.3 Rising Demand for Outsourcing Services
1.3 Regulatory Landscape
1.3.1 Asia-Pacific
1.3.1.1 China
1.3.1.2 Japan
1.4 Supply Chain Analysis
1.4.1 Supply Chain and Risks within the Supply Chain
1.5 Patent Analysis
1.5.1 Patent Filing Trend (by Country)
1.5.2 Patent Filing Trend (by Year)
1.6 Market Dynamics
1.6.1 Market Drivers
1.6.1.1 Rising Prevalence of Chronic and Rare Diseases Driving Demand for Biologics in Treatment
1.6.1.2 Strong Investment and R&D Funding Leading to Increased Demand for Biologics
1.6.2 Market Challenges
1.6.2.1 High Development and Manufacturing Costs Hindering the Growth of the Market
1.6.3 Market Opportunities
1.6.3.1 AI Integration in Biologics Discovery
2 Biologics Drug Discovery Market (by Region), ($Billion), 2023-2035
2.1 Asia-Pacific
2.1.1 Regional Overview
2.1.2 Driving Factors for Market Growth
2.1.3 Factors Challenging the Market
2.1.4 Market Sizing and Forecast
2.1.4.1 Asia-Pacific Biologics Drug Discovery Market, by Manufacturing Type
2.1.4.2 Asia-Pacific Biologics Drug Discovery Market, by Type
2.1.4.3 Asia-Pacific Biologics Drug Discovery Market, by Country
2.1.4.3.1 China
2.1.4.3.1.1 Country Overview
2.1.4.3.1.2 Driving Factors for Market Growth
2.1.4.3.1.3 Factors Challenging the Market
2.1.4.3.1.4 Market Sizing and Forecast
2.1.4.3.1.4.1 China Biologics Drug Discovery Market, by Manufacturing Type
2.1.4.3.1.4.2 China Biologics Drug Discovery Market, by Type
2.1.4.3.2 Japan
2.1.4.3.2.1 Country Overview
2.1.4.3.2.2 Driving Factors for Market Growth
2.1.4.3.2.3 Factors Challenging the Market
2.1.4.3.2.4 Market Sizing and Forecast
2.1.4.3.2.4.1 Japan Biologics Drug Discovery Market, by Manufacturing Type
2.1.4.3.2.4.2 Japan Biologics Drug Discovery Market, by Type
2.1.4.3.3 India
2.1.4.3.3.1 Country Overview
2.1.4.3.3.2 Driving Factors for Market Growth
2.1.4.3.3.3 Factors Challenging the Market
2.1.4.3.3.4 Market Sizing and Forecast
2.1.4.3.3.4.1 India Biologics Drug Discovery Market, by Manufacturing Type
2.1.4.3.3.4.2 India Biologics Drug Discovery Market, by Type
2.1.4.3.4 South Korea
2.1.4.3.4.1 Country Overview
2.1.4.3.4.2 Driving Factors for Market Growth
2.1.4.3.4.3 Factors Challenging the Market
2.1.4.3.4.4 Market Sizing and Forecast
2.1.4.3.4.4.1 South Korea Biologics Drug Discovery Market, by Manufacturing Type
2.1.4.3.4.4.2 South Korea Biologics Drug Discovery Market, by Type
2.1.4.3.5 Australia
2.1.4.3.5.1 Country Overview
2.1.4.3.5.2 Driving Factors for Market Growth
2.1.4.3.5.3 Factors Challenging the Market
2.1.4.3.5.4 Market Sizing and Forecast
2.1.4.3.5.4.1 Australia Biologics Drug Discovery Market, by Manufacturing Type
2.1.4.3.5.4.2 Australia Biologics Drug Discovery Market, by Type
2.1.4.3.6 Rest-of-Asia-Pacific
2.1.4.3.6.1 Country Overview
2.1.4.3.6.2 Driving Factors for Market Growth
2.1.4.3.6.3 Factors Challenging the Market
2.1.4.3.6.4 Market Sizing and Forecast
2.1.4.3.6.4.1 Rest-of-Asia-Pacific Biologics Drug Discovery Market, by Manufacturing Type
2.1.4.3.6.4.2 Rest-of-Asia-Pacific Biologics Drug Discovery Market, by Type
3 Competitive Benchmarking and Company Profiles
3.1 Company Profiles
3.1.1 Astellas Pharma Inc.
3.1.1.1 Overview
3.1.1.2 Top Products/Product Portfolio
3.1.1.3 Top Competitors
3.1.1.4 Target Customers
3.1.1.5 Key Personal
3.1.1.6 Analyst View
3.1.2 GenScript Biotech Corporation
3.1.2.1 Overview
3.1.2.2 Top Products/Product Portfolio
3.1.2.3 Top Competitors
3.1.2.4 Target Customers
3.1.2.5 Key Personal
3.1.2.6 Analyst View
3.1.3 WuXi Biologics (Cayman) Inc.
3.1.3.1 Overview
3.1.3.2 Top Products/Product Portfolio
3.1.3.3 Top Competitors
3.1.3.4 Target Customers
3.1.3.5 Key Personal
3.1.3.6 Analyst View
4 Research Methodology
4.1 Data Sources
4.1.1 Primary Data Sources
4.1.2 Secondary Data Sources
4.1.3 Data Triangulation
4.2 Market Estimation and Forecast
List of Figure
Figure 1: Asia-Pacific Biologics Drug Discovery Market (by Scenario), $Billion, 2024, 2029, and 2035
Figure 2: Asia-Pacific Biologics Drug Discovery Market, 2024 and 2035
Figure 3: Biologics Drug Discovery Market, $Billion, 2025 and 2035
Figure 4: Asia-Pacific Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2025, 2029, and 2035
Figure 5: Asia-Pacific Biologics Drug Discovery Market (by Type), $Billion, 2025, 2029, and 2035
Figure 6: Number of Patents Filed (by Country), January 2021 to 12th September 2025
Figure 7: Number of Patents Filed (by Year), January 2021 to 12th September 2025
Figure 8: Incidence of Cancer (by Region), 2020-2040
Figure 9: Asia-Pacific Biologics Drug Discovery Market, $Billion, 2023-2035
Figure 10: China Biologics Drug Discovery Market, $Billion, 2023-2035
Figure 11: Japan Biologics Drug Discovery Market, $Billion, 2023-2035
Figure 12: India Biologics Drug Discovery Market, $Billion, 2023-2035
Figure 13: South Korea Biologics Drug Discovery Market, $Billion, 2023-2035
Figure 14: Australia Biologics Drug Discovery Market, $Billion, 2023-2035
Figure 15: Rest-of-Asia-Pacific Biologics Drug Discovery Market, $Billion, 2023-2035
